Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids

Oncologist

Volumn 18, Issue 2, 2013, Pages 212-220

  Reddy, Akhila ^a   Yennurajalingam, Sriram ^a   Pulivarthi, Kalyan ^a   Palla, Shana L ^a   Wang, Xuan ^a   Kwon, Jung Hye ^a,b   Frisbee Hume, Susan ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Hallym University Medical Center   (South Korea)

Author keywords

Opioid rotation; Opioid induced neurotoxicity; Outpatient; Pain; Palliative care

Indexed keywords

MORPHINE; OPIATE;

ADULT; ARTICLE; CANCER PAIN; DELIRIUM; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NEUROTOXICITY; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SYMPTOM ASSESSMENT; SYMPTOM DISTRESS SCALE; TREATMENT OUTCOME;

AGED; ANALGESICS, OPIOID; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PAIN MANAGEMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874353658     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0269     Document Type: Article

References (42)

1. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695-1700.
2. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990;804:1-75.
3. Lotsch J. Opioid metabolites. J Pain Symptom Manage 2005;29:S10-S24.
4. Mercadante S, Portenoy RK. Opioid poorlyresponsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001;21:144-150.
5. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: The science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009; 38:426-439.
6. Paix A, Coleman A, Lees J et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995;63:263-269.
7. MacDonald N, Der L, Allan S et al. Opioid hyper-excitability: The application of alternate opioid therapy. Pain 1993;53:353-355.
8. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994;59:313-316.
9. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-384.
10. Maddocks I, Somogyi A, Abbott F et al. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996;12:182-189.
11. Ashby MA, Martin P, Jackson KA. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust 1999;170:68-71.
12. Kloke M, Rapp M, Bosse B et al. Toxicity and/or insufficient analgesia by opioid therapy: Risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer 2000;8:479-486.
13. Mercadante S, Bruera E. Opioid switching: A systematic and critical review. Cancer Treat Rev 2006;32:304-315.
14. Fine PG, Portenoy RK. Establishing "best practices" for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage 2009;38: 418-425.
15. Hawley P, Forbes K, Hanks GW. Opioids, confusion and opioid rotation. Palliat Med 1998;12: 63-64.
16. Twycross R. Opioid rotation: Does it have a role? Palliat Med 1998;12:60-63.
17. Mercadante S. Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 1999;86: 1856-1866.
18. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: Opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med 2011; 25:494-503.
19. Mercadante S, Ferrera P, Villari P et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009;37:632-641.
20. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004:CD004847.
21. Osta BE, Palmer JL, Paraskevopoulos T et al. Interval between first palliative care consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med 2008;11:51-57.
22. Hui D, Parsons H, Nguyen L et al. Timing of palliative care referral and symptom burden in phase 1 cancer patients: A retrospective cohort study. Cancer 2010;116:4402-4409.
23. Yennurajalingam S, Kang JH, Hui D et al. Clinical response to an outpatient palliative care consultation in patients with advanced cancer and cancer pain. J Pain Symptom Manage 2012;44:340-350.
24. Parsons HA, de la Cruz M, El Osta B et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116: 520-528.
25. Bruera E, Kuehn N, Miller MJ et al. The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9.
26. Breitbart W, Rosenfeld B, Roth A et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997;13:128-137.
27. Bush B, Shaw S, Cleary P et al. Screening for alcohol abuse using the CAGE questionnaire. Am J Med 1987;82:231-235.
28. Yennurajalingam S, Urbauer DL, Casper KL et al. Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic. J Pain Symptom Manage 2011;41:49-56.
29. Elsayem A, Bruera E. The MD Anderson Symptom Control and Palliative Care Handbook. Houston, TX: University of Health Science Center at Houston, 2008.
30. Walker PW, Palla S, Pei BL et al. Switching from methadonetoadifferentopioid:whatistheequianalgesic dose ratio? J Palliat Med 2008;11:1103-1108.
31. Carvajal A, Centeno C, Watson R, Bruera E. A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients. Eur J Cancer 2011;47:1863-1872.
32. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: A validation study. J Pain Symptom Manage 2003;25: 406-411.
33. Muller-Busch HC, Lindena G, Tietze K et al. Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain 2005;9:571-579.
34. Fisch MJ, Lee JW, Weiss M et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 2012;30:1980-1988.
35. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med 2012;13:562-570.
36. Webster LR, Fine PG. Overdose deaths demand a new paradigm for opioid rotation. Pain Med 2012;13:571-574.
37. Mercadante S. Switching methadone: A 10-year experience of 345 patients in an acute palliative care unit. Pain Med 2012;13:399-404.
38. Fredheim OM, Moksnes K, Borchgrevink PC et al. Opioid switching to methadone: A pharmacoepi-demiological study from a national prescription database. Palliat Med 2012; 26:804-812.
39. Ripamonti C, Fagnoni E, Campa T et al. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 2006;14:400-407.
40. Cleeland CS, Gonin R, Hatfield AK et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-596.
41. Mercadante S, Ferrera P, Casuccio A. Outcome of opioid switching 4 weeks after discharge from a palliative care unit. Curr Med Res Opin 2011;27: 2357-2360.
42. Bruera E, Franco JJ, Maltoni M et al. Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995;10:287-291.